drugset / Trial / NCT03177291
Pirfenidone Combined With Standard First-Line Chemotherapy in Advanced-Stage Lung NSCLC
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to find out what effects (good and/or bad) Pirfenidone combined with standard first-line chemotherapy will have on you and non-small cell lung cancer (NSCLC). The investigational drug Pirfenidone is being combined with standard chemotherapy in participants with advanced non-small cell lung cancer. Pirfenidone is approved to treat idiopathic pulmonary fibrosis (IPF) but it isn't currently approved to treat non-small cell lung cancer.
Timeline
- Start
- 2017-09-26
- Primary completion
- 2021-05-09
- Completion
- 2024-12-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Pirfenidone | Small molecule | 267 mg | Oral |
| Comparator | Pirfenidone | Small molecule | 534 mg | Oral |
| Comparator | Pirfenidone | Small molecule | 801 mg | Oral |
| Comparator | Carboplatin | Small molecule | 6 unknown | — |
| Comparator | Paclitaxel | Small molecule | 200 mg/m2 | — |
| Comparator | Pemetrexed | Small molecule | 500 mg/m2 | — |